CD8A and neoplasm: Moreover, pembrolizumab-refractory xenograft tumors exhibited reduced fractions of CD8+ T-cells, memory B cells, and plasma cells, as well as increased proportions of naïve M0 macrophages and activated mast cells, compared to PBS control tumor tissues.